Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels.
about
Some considerations on the predictions of pharmacokinetic alterations in subjects with liver disease.Influence of kidney disease on drug disposition: An assessment of industry studies submitted to the FDA for new chemical entities 1999-2010.Role of enterohepatic recirculation in drug disposition: cooperation and complications.Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact.Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development.
P2860
Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels.
@en
Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels.
@nl
type
label
Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels.
@en
Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels.
@nl
prefLabel
Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels.
@en
Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels.
@nl
P2093
P2860
P356
P1476
Evaluation of hepatic impairment dosing recommendations in FDA-approved product labels.
@en
P2093
Gilbert J Burckart
Lawrence J Lesko
Yang Chang
P2860
P304
P356
10.1002/JCPH.128
P577
2013-07-07T00:00:00Z